RESUMO
Muscle atrophy occurs as a consequence of a number of conditions, including cancer, chronic obstructive pulmonary disease (COPD), diabetes mellitus, heart failure, and other chronic diseases, where it is generally a predictor of poor survival. It also occurs as a consequence of disuse and an age-related loss of muscle mass and strength (sarcopenia). The aims of the 2016, International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force were to examine how these specific chronic conditions have been employed in treatment trials thus far and how future trials using these patient groups might be designed for efficient identification of effective sarcopenia interventions. Functional limitations assessed as gait speed, distance walked over a set time period, or other attributes of physical performance have been suggested as outcome measures in sarcopenia trials. Indeed, such measures have already been used successfully in a number of trials aimed at preventing disability in older adults.
Assuntos
Anticorpos Bloqueadores/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Dietoterapia , Terapia por Exercício , Atrofia Muscular/terapia , Sarcopenia/terapia , Absorciometria de Fóton , Comitês Consultivos , Anticorpos Monoclonais Humanizados , Ensaios Clínicos como Assunto , Diabetes Mellitus Tipo 2/complicações , Marcha , Insuficiência Cardíaca/complicações , Fraturas do Quadril/complicações , Humanos , Imageamento por Ressonância Magnética , Espectroscopia de Ressonância Magnética , Atrofia Muscular/complicações , Atrofia Muscular/diagnóstico por imagem , Atrofia Muscular/fisiopatologia , Obesidade/complicações , Avaliação de Resultados em Cuidados de Saúde , Doença Pulmonar Obstrutiva Crônica/complicações , Sarcopenia/complicações , Sarcopenia/diagnóstico por imagem , Sarcopenia/fisiopatologia , Tomografia Computadorizada por Raios X , Resultado do Tratamento , Teste de CaminhadaRESUMO
At the Drug Information Association (DIA) 49th annual meeting, for the first time regulators (Dr Francesca Cerreta, Dr Robert Temple and Dr Yasuko Asahina) from the three International Conference on Harmonization (ICH) co-sponsor regions came together in a forum to discuss their perspective on how the aging population impacts on drug development and on the design of clinical trials. In 2010, the ICH E7 Guideline (Studies in support of Special Populations: Geriatrics) was revised with the addition of a Questions and Answers document to take into account the rapidly changing world demographics. Regulators from the three ICH regions (Europe, USA and Japan) discuss here how they foresee the application of this guideline, and the impact that this might have on new drug development and clinical trial design. This article aims to summarize the discussions at the session for the benefit of a wider audience.
Assuntos
Envelhecimento , Geriatria/tendências , Órgãos Governamentais/legislação & jurisprudência , Regulamentação Governamental , Guias como Assunto , Necessidades e Demandas de Serviços de Saúde/tendências , Distribuição por Idade , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Ensaios Clínicos como Assunto/métodos , Ensaios Clínicos como Assunto/tendências , Congressos como Assunto , Descoberta de Drogas/métodos , Descoberta de Drogas/tendências , Europa (Continente) , Humanos , Cooperação Internacional , Japão , Estados UnidosRESUMO
UNLABELLED: Frailty tends to be considered as a major risk for adverse outcomes in older persons, but some important aspects remain matter of debate. OBJECTIVES: The purpose of this paper is to present expert's positions on the main aspects of the frailty syndrome in the older persons. PARTICIPANTS: Workshop organized by International Association of Gerontology and Geriatrics (IAGG), World Health Organization (WHO) and Société Française de Gériatrie et de Gérontologie (SFGG). RESULTS: Frailty is widely recognized as an important risk factor for adverse health outcomes in older persons. This can be of particular value in evaluating non-disabled older persons with chronic diseases but today no operational definition has been established. Nutritional status, mobility, activity, strength, endurance, cognition, and mood have been proposed as markers of frailty. Another approach calculates a multidimensional score ranging from "very fit" to "severely frail", but it is difficult to apply into the medical practice. Frailty appears to be secondary to multiple conditions using multiple pathways leading to a vulnerability to a stressor. Biological (inflammation, loss of hormones), clinical (sarcopenia, osteoporosis etc.), as well as social factors (isolation, financial situation) are involved in the vulnerability process. In clinical practice, detection of frailty is of major interest in oncology because of the high prevalence of cancer in older persons and the bad tolerance of the drug therapies. Presence of frailty should also be taken into account in the definition of the cardiovascular risks in the older population. The experts of the workshop have listed the points reached an agreement and those must to be a priority for improving understanding and use of frailty syndrome in practice. CONCLUSION: Frailty in older adults is a syndrome corresponding to a vulnerability to a stressor. Diagnostic tools have been developed but none can integrate at the same time the large spectrum of factors and the simplicity asked by the clinical practice. An agreement with an international common definition is necessary to develop screening and to reduce the morbidity in older persons.